Tirzepatide 30mg injection vials

Product Overview‌
Tirzepatide 30mg is a cutting-edge dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist designed to support glycemic control and sustainable weight management in adults with type 2 diabetes mellitus. Manufactured under strict cGMP guidelines, our formulation delivers precision dosing for optimal therapeutic outcomes.

Dosage & Administration‌

• ‌Initial Dose‌: 2.5mg weekly for 4 weeks (titration phase).
• ‌Maintenance Dose‌: Gradually increase to 5mg, 10mg, or 15mg based on tolerance. ‌Maximum recommended dose: 30mg/week‌.
• ‌Administration‌: Inject subcutaneously in abdomen, thigh, or upper arm. Rotate injection sites.

‌Side Effects‌
Common (≥5%): Nausea, diarrhea, decreased appetite, mild hypoglycemia.
Serious (Seek immediate care): Pancreatitis symptoms, severe allergic reactions, renal impairment.

‌Important Precautions‌
‌Contraindications‌: Hypersensitivity to Tirbepatide or components; personal/family history of medullary thyroid carcinoma.
‌Warnings‌: Monitor for pancreatitis, diabetic retinopathy complications, and acute gallbladder disease. ‌Pregnancy/Nursing‌: Not recommended; consult healthcare provider.

‌Storage‌

• Store at 2°C–8°C (36°F–46°F) before first use.
• After initial use, keep at ≤30°C for up to 28 days. Protect from light.